Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba® When Administered to Immunocompromised Participants ≥10 Years of Age
Final Report – A Phase 4, Open-Label, Single-Arm Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba® When Administered to Immunocompromised Participants ≥10 Years of Age
Category & Conditions: Infections and Infectious Diseases
Medicine: TRUMENBA™(MENINGOCOCCAL GROUP B VACCINE)
ClinicalTrials.gov Identifier (NCT): NCT04893811
Protocol ID: B1971060
Open Plain Language Summary Result:
Click here